The FDA grants fast track designation of AstraZeneca's dapagliflozin; California to conduct public awareness campaign against vaping; no new US measles cases.
AstraZeneca announced yesterday that the FDA has granted fast track designation for the development of dapagliflozin, sold as Farxiga, to reduce the risk of cardiovascular (CV) death or worsening of heart failure in adults with heart failure and reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). The announcement follows last month’s FDA fast track designation of dapagliflozin to delay the progression of renal failure and prevent CV and renal death in patients with chronic kidney disease. The decision was based on 2 phase 3 trials, DAPA-HF and DELIVER, which investigated the role of dapagliflozin in patients with heart failure and HFrEF or HFpEF.Governor Gavin Newsom, D-California, announced yesterday that the state will spend $20 million on a public awareness campaign about the dangers of vaping nicotine and cannabis products, according to the Los Angeles Times. The move comes amid the nationwide rise in vaping-related illnesses and will increase efforts to stop the sale of illicit products. California has reported at least 63 cases, and 1 death, in association to these vaping-related lung illnesses. Many cases have been linked to the use of cannabis-based oils, but the CDC reports that some affected individuals were vaping nicotine products. The public awareness campaign will tackle all forms of vaping, added Newsom.The United States’ worst measles epidemic in 27 years may be in its final stages as no new cases were reported in the last week, according to The Associated Press. The epidemic emerged last year when travelers who had become infected overseas spread the disease to unvaccinated people, with most cases reported in Orthodox Jewish communities in and around New York City. This year, 1241 cases have been reported which has threatened to remove the disease elimination status held by the United States for over 2 decades. If no new cases occur, the epidemic will be set to end on or near September 30.
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
ATTR-CA Variant Disproportionately Impacts Black Individuals With Heart Failure
September 16th 2025The transthyretin cardiac amyloidosis (ATTR-CA) variant is more prevalent in Black individuals, increasing the need for more research to assess hereditary links and early prevention awareness.
Read More
Racial, Ethnic Disparities May Impact Age Differences at First Heart Failure Hospitalization
September 4th 2025Social determinants of health were associated with a younger age of first hospitalization for heart failure in Black and Hispanic patients when compared with Asian and White patients.
Read More